Ardelyx will need to demonstrate better cost management over time for investors to build confidence here. Click here to find ...

On February 19, 2026, Ardelyx reported its fourth-quarter and full-year 2025 results, highlighting a 73% surge in IBSRELA revenue to $274.2 million and total revenue of $407.3 million, alongside $103.

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain ...

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. Ardelyx, Inc. (NASDAQ:ARDX) reported preliminary, unaudited product revenue results for the fourth quarter and full ...

XPHOZAH® (tenapanor) finishes 2025 with $103.6 million in revenue Revenue for XPHOZAH in 2025 was $103.6 million reflecting year-over-year growth in total XPHOZAH dispenses, including an increased ...

Ardelyx Inc (ARDX) reports a 22% revenue increase in 2025, driven by Ibsrela's strong performance, despite facing increased losses and operational expenses.

Plenty of brands are already sharing or teasing their Super Bowl 2026 ads. Here are the best commercials we've seen so far ...

Q4 2025 Earnings Call February 19, 2026 4:30 PM ESTCompany ParticipantsCaitlin Lowie - Vice President of Corporate Communications ...

IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs fo ...

The gut microbiome is now understood to be one of the most influential systems in the body: a vast community of bacteria, ...

Foods like lentils, raspberries, avocados, chia seeds, and barley provide significantly more fiber per serving than apples ...